The size of the Global Hemophilia Management Market was worth USD 5.35 billion in 2019 and estimated to be growing at a CAGR of 1.62%, to reach USD 5.8 billion by 2024. Hemophilia is a genetic disorder that impairs the body`s ability to control blood clotting. Hemophilia usually occurs in males it is estimated that about 1 in 5000 males that are born each year contain hemophilia.
Hemophilia is categorized into three levels depending on its severity as severe, moderate and mild. About 80% of the hemophilia patients are considered to suffer from severe type. The worldwide incidence of hemophilia is estimated at more than 400,000 people. It is estimated that about 75% of the hemophilia patients do not receive adequate treatment.
Key Market Growth Drivers
The growing prevalence of the disease and increasing usage of the recombinant product is expected to drive the market growth. Technological advancements and advancements in the novel coagulating factors and are also fuelling the growth of global Hemophilia Management market. Rising investments in Research and developments for hemophilia products are also driving the market growth.
Major Challenges
However, lack of available medication, awareness of this disease and high cost of treatment are the major restraining factors in the market.
Potential Opportunities
Advancements in gene therapy and an increasing number of drug approvals for the treatment of hemophilia provide immense growth opportunities in the market.
Details of the report:
|
Report Metric |
Details |
|
Market Size Available |
2018 – 2024 |
|
Base Year |
2018 |
|
Forecast Period |
2019 - 2024 |
|
Segments Covered |
By Type, Drug, Region |
|
Various Analyses Covered |
Global, Regional & Country Level Analysis, Segment-Level Analysis, DROC, PESTLE Analysis, Porter’s Five Forces Analysis, Competitive Landscape, Analyst Overview on Investment Opportunities |
|
Regions Covered |
North America, Europe, APAC, Latin America, Middle East & Africa |
|
Market Leaders Profiled |
Biogen, Baxter International Inc., Pfizer Inc., Bayer Pharma AG, Novo Nordisk A/S, Grifols International SA, CSL Behring, Octapharma, Swedish Orphan Biovitrum AB |
In this research report, the Global Hemophilia Management Market has been segmented and sub-segmented into the following categories and calculated the market size and forecast for each segment until 2024.
Hemophilia Management Market - By Type:
On the basis of type, Hemophilia A segment is projected to have the highest growth rate driven by a large number of patients suffering from hemophilia A
Hemophilia Management Market - By Drug:
Hemophilia Management Market - By Region:
North America is the largest market for hemophilia management accounting for approximately XX% due to high government support and the increasing number of patients suffering from hemophilia.
Europe is the second-largest market for hemophilia management.
Asia-Pacific region is estimated to be the fastest-growing region owing to its high population base and increasing healthcare expenditure.
Latin America region provides a lucrative opportunity for growth attributed to local government support and the increasing focus of global players towards emerging economies.
Key market participants
Below are few of the companies playing a dominating role in the Global Hemophilia Management Market
1.1 Market Definition
1.2 Study Deliverables
1.3 Base Currency, Base Year and Forecast Periods
1.4 General Study Assumptions
2.1 Introduction
2.2 Research Phases
2.2.1 Secondary Research
2.2.2 Primary Research
2.2.3 Econometric Modelling
2.2.4 Expert Validation
2.3 Analysis Design
2.4 Study Timeline
3.1 Executive Summary
3.2 Key Inferences
3.3 New Developments
4.1 Market Drivers
4.2 Market Restraints
4.3 Key Challenges
4.4 Current Opportunities in the Market
5.1 BY Type
5.1.1 Hemophilia A
5.1.2 Hemophilia B
5.2 By Drug
5.2.1 Octocogalfa
5.2.2 Nonacogalfa
5.2.3 Desmopressin
5.2.4 Other drugs
6.1 North America
6.1.1 Introduction
6.1.2 United States
6.1.3 Canada
6.2 Europe
6.2.1 Introduction
6.2.2 U.K
6.2.3 Spain
6.2.4 Germany
6.2.5 Italy
6.2.6 France
6.3 Asia-Pacific
6.3.1 Introduction
6.3.2 China
6.3.3 India
6.3.4 Japan
6.3.5 South Korea
6.3.6 Australia
6.4 Latin America
6.4.1 Introduction
6.4.2 Brazil
6.4.3 Mexico
6.4.4 Argentina
6.5 Middle East & Africa
6.5.1 Introduction
6.5.2 Middle-East
6.5.3 Africa
7.1 PESTLE analysis
7.1.1 Political
7.1.2 Economic
7.1.3 Social
7.1.4 Technological
7.1.5 Legal
7.1.6 Environmental
7.2 Porter’s Five analysis
7.2.1 Bargaining Power of Suppliers
7.2.2 Bargaining Power of Consumers
7.2.3 Threat of New Entrants
7.2.4 Threat of Substitute Products and Services
7.2.5 Competitive Rivalry within the Industry
8.1 Biogen
8.1.1 Overview
8.1.2 Product Analysis
8.1.3 Strategic Evaluation and Operations
8.1.4 Financial analysis
8.1.5 Legal issues
8.1.6 Recent Developments
8.1.7 SWOT analysis
8.1.8 Analyst View
8.2 Pfizer Inc.
8.3 Baxter International Inc.
8.4 Bayer Pharma AG
8.5 Novo Nordisk A/S
8.6 Grifols International SA
8.7 CSL Behring
8.8 Octapharma
8.9 Swedish Orphan Biovitrum AB
9.1 Market share analysis
9.2 Merger and Acquisition Analysis
9.3 Agreements, collaborations and Joint Ventures
9.4 New Product Launches
10.1 Market Outlook
10.2 Investment Opportunities
Appendix
a) List of Tables
b) List of Figures
Related Reports
Aug 2019
Download Sample
Aug 2019
Download Sample
Aug 2019
Download Sample
Aug 2019
Download Sample
